Control of Trypanosoma cruzi infection and changes in T-cell populations induced by a therapeutic DNA vaccine in mice

Zapata-Estrella, Hiatzy; Hummel-Newell, Caroline; Sánchez-Burgos, Gilma Guadalupe; Escobedo-Ortegón, Javier; Ramírez-Sierra, María Jesús; Arjona-Torres, Arletty; Dumonteil, Eric

doi:10.1016/j.imlet.2005.11.015

Cited by 53 publications

(45 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…59,60 It is thus of key interest that the same antigens and vaccine formulations may be used for both the prevention of Chagas disease as well as for the therapy of an ongoing infection, making these a very flexible tool for disease control.…”

Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tmentioning

confidence: 99%

Advances and challenges towards a vaccine against Chagas disease

Quijano-Hernández

Dumonteil

2011

Human Vaccines

View full text Add to dashboard Cite

Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tmentioning

confidence: 99%

Advances and challenges towards a vaccine against Chagas disease

Quijano-Hernández

Dumonteil

2011

Human Vaccines

View full text Add to dashboard Cite

“…For T. cruzi, immunization trials (as a protective or therapeutic vaccine) based on a cysteine protease or a trans-sialidase have been mentioned (30,76,161).…”

Section: Antidisease Treatmentsmentioning

confidence: 99%

Host-Parasite Interactions in Trypanosomiasis: on the Way to an Antidisease Strategy

2009

View full text Add to dashboard Cite

“…An alternative approach for therapy is a therapeutic vaccine, and the effectiveness of a therapeutic vaccine in mice has been demonstrated by Dumonteil et al (5,24). To further explore the ability of immunotherapy to affect the T. cruzi-induced immune response, we subjected C57BL/6 mice infected with the T. cruzi CL strain to adoptive transfer or immunized them with the SA85-1.1 protein after the acute phase had resolved.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, if a T. cruzi vaccine advances to use in people, it is possible that the vaccine will be administered during acute infection. Although other experimental mouse studies have demonstrated that a protective vaccine administered during acute infection does not exacerbate inflammation, it will important for other investigators to provide similar preclinical safety data using other vaccine candidates (5,24).…”

Section: Discussionmentioning

confidence: 99%

“…Despite these concerns, several T. cruzi proteins have been used as immunogens in mice to augment the acute immune response and to better control parasitemia and improve survival (8-10, 15-17, 20-22). Furthermore, a therapeutic vaccine administered to mice during acute or chronic infection has been shown to augment the anti-T. cruzi immune response and to decrease tissue inflammation (5,24). These reports argue that safe and effective vaccines for prevention and treatment of Chagas' disease can be developed.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Parasite-Induced Chronic Inflammation Is Not Exacerbated by Immunotherapy before or duringTrypanosoma cruziInfection

Duthie

Kahn

Zakayan

et al. 2007

Clin Vaccine Immunol

View full text Add to dashboard Cite

Trypanosoma cruzi infection causes Chagas' disease, a chronic inflammatory disease. The specific inflammatory responses that cause Chagas' disease remain unclear, but data argue that parasites that persist in the host stimulate chronic self-damaging immune responses. Because T. cruzi appears to stimulate self-damaging responses, the enthusiasm to develop vaccines that boost antiparasite responses that might increase selfdamaging responses has been limited. We previously demonstrated that immunization with a T. cruzi transsialidase protein or adoptive transfer of trans-sialidase-specific T-cell clones decreased parasitemia, morbidity, and mortality. Here we report that immunization or adoptive transfer with the protein or clones, before or during T. cruzi infection, boosts the anti-T. cruzi immune response without exacerbating acute or chronic tissue inflammation. These results argue that prophylactic and therapeutic immunotherapy for Chagas' disease can be developed safely.

show abstract

Control of Trypanosoma cruzi infection and changes in T-cell populations induced by a therapeutic DNA vaccine in mice

Cited by 53 publications

References 40 publications

Advances and challenges towards a vaccine against Chagas disease

Advances and challenges towards a vaccine against Chagas disease

Host-Parasite Interactions in Trypanosomiasis: on the Way to an Antidisease Strategy

Parasite-Induced Chronic Inflammation Is Not Exacerbated by Immunotherapy before or duringTrypanosoma cruziInfection

Contact Info

Product

Resources

About